Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
Pliant Therapeutics (PLRX) has appointed Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience across multiple drug modalities. In her new role, she will lead chemistry, manufacturing and control (CMC)-related activities supporting Pliant's commercial-stage readiness plan.
Dr. Imbert most recently served as Senior Vice President of CMC and Technical Operations at Chinook Therapeutics (acquired by Novartis), where she managed a fully outsourced CMC, manufacturing and supply chain organization. Previously, she held senior roles at Dermira (acquired by Eli Lily) and Anacor Pharmaceuticals (acquired by Pfizer), demonstrating expertise in pharmaceutical development, manufacturing processes, supply chain, logistics, and regulatory filings.
Pliant Therapeutics (PLRX) ha nominato Delphine Imbert, Ph.D. come Chief Technical Officer. La Dott.ssa Imbert porta con sé 25 anni di esperienza nel passaggio dalla fase clinica alla produzione commerciale e nello sviluppo di farmaci in vari ambiti terapeutici. Nel suo nuovo ruolo, guiderà le attività relative alla chimica, produzione e controllo (CMC) a supporto del piano di preparazione commerciale di Pliant.
Recentemente, la Dott.ssa Imbert ha ricoperto il ruolo di Vice Presidenza Senior di CMC e Operazioni Tecniche presso Chinook Therapeutics (acquisita da Novartis), dove ha gestito un'organizzazione di CMC, produzione e supply chain completamente esternalizzata. In precedenza, ha ricoperto ruoli di alto livello presso Dermira (acquisita da Eli Lilly) e Anacor Pharmaceuticals (acquisita da Pfizer), dimostrando competenza nello sviluppo farmaceutico, nei processi di produzione, nella supply chain, nella logistica e nelle pratiche di regolamentazione.
Pliant Therapeutics (PLRX) ha nombrado a Delphine Imbert, Ph.D. como Directora Técnica. La Dr. Imbert aporta 25 años de experiencia en la evolución de la fabricación clínica a la comercial y en el desarrollo de fármacos en múltiples modalidades. En su nuevo cargo, liderará las actividades relacionadas con la química, la fabricación y el control (CMC) que apoyan el plan de preparación para la etapa comercial de Pliant.
Recientemente, la Dr. Imbert se desempeñó como Vicepresidenta Senior de CMC y Operaciones Técnicas en Chinook Therapeutics (adquirida por Novartis), donde gestionó una organización de CMC, fabricación y cadena de suministro completamente externalizada. Anteriormente, ocupó puestos de alto nivel en Dermira (adquirida por Eli Lilly) y Anacor Pharmaceuticals (adquirida por Pfizer), demostrando experiencia en el desarrollo farmacéutico, procesos de fabricación, cadena de suministro, logística y presentaciones regulatorias.
Pliant Therapeutics (PLRX)는 Delphine Imbert, Ph.D.를 최고 기술 책임자로 임명했습니다. Imbert 박사는 여러 약물 형태에 걸쳐 임상 단계에서 상업 단계로의 제조 및 약물 개발 경험이 25년에 달합니다. 그녀는 새로운 역할에서 Pliant의 상업 단계 준비 계획을 지원하는 화학, 제조 및 품질 관리(CMC) 관련 활동을 이끌 것입니다.
Imbert 박사는 최근 Chinook Therapeutics(노바티스에 인수됨)의 CMC 및 기술 운영 수석 부사장직을 맡아 완전히 아웃소싱된 CMC, 제조 및 공급망 조직을 관리했습니다. 이전에는 Dermira(엘리 릴리에 인수됨)와 Anacor Pharmaceuticals(화이자에 인수됨)에서 고위직을 맡아 제약 개발, 제조 프로세스, 공급망, 물류 및 규제 제출에 대한 전문성을 보여주었습니다.
Pliant Therapeutics (PLRX) a nommé Delphine Imbert, Ph.D. au poste de Directrice Technique. Dr. Imbert apporte 25 ans d'expérience stratégique dans le passage de l'étape clinique à la fabrication et au développement de médicaments à travers plusieurs modalités thérapeutiques. Dans son nouveau rôle, elle dirigera les activités liées à la chimie, à la fabrication et au contrôle (CMC) soutenant le plan de préparation commercial de Pliant.
Dr. Imbert a récemment été vice-présidente senior de CMC et des opérations techniques chez Chinook Therapeutics (acquise par Novartis), où elle a géré une organisation CMC, fabrication et chaîne d'approvisionnement entièrement externalisée. Auparavant, elle a occupé des postes de direction chez Dermira (acquise par Eli Lilly) et Anacor Pharmaceuticals (acquise par Pfizer), montrant son expertise dans le développement pharmaceutique, les processus de fabrication, la chaîne d'approvisionnement, la logistique et les dépôts réglementaires.
Pliant Therapeutics (PLRX) hat Delphine Imbert, Ph.D. zur Chief Technical Officer ernannt. Dr. Imbert bringt 25 Jahre Erfahrung in der strategischen klinischen und kommerziellen Produktions- sowie Arzneimittelentwicklungsbranche in verschiedenen Arzneimittelmodellen mit. In ihrer neuen Rolle wird sie die chemischen, Herstellungs- und Kontrollaktivitäten (CMC) leiten, die Pliants Plan zur Marktreife unterstützen.
Zuletzt arbeitete Dr. Imbert als Senior Vice President für CMC und technische Operationen bei Chinook Therapeutics (erworben von Novartis), wo sie eine vollständig ausgelagerte CMC-, Produktions- und Lieferkettenorganisation leitete. Zuvor hatte sie leitende Funktionen bei Dermira (erworben von Eli Lilly) und Anacor Pharmaceuticals (erworben von Pfizer) inne und zeigte Fachwissen in der pharmazeutischen Entwicklung, Produktionsprozessen, Lieferketten, Logistik und regulatorischen Einreichungen.
- Appointment of an experienced executive with 25 years of relevant industry expertise
- Strategic hire aligned with commercial-stage preparation for bexotegrast
- Dr. Imbert's proven track record in managing successful drug development programs through approval and launch
- None.
Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of product development, process optimization and manufacturing experience across multiple drug modalities, including small molecules. In this role, Dr. Imbert will lead chemistry, manufacturing and control (CMC)-related activities in support of Pliant’s commercial-stage readiness plan.
“Delphine is an experienced CMC strategy and operations leader who has built high-performing organizations resulting in the successful advancement of small molecule drugs from development through approval and launch,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “Delphine’s breadth of pharmaceutical development experience, including manufacturing processes, supply chain, logistics and sourcing, as well as associated regulatory filings, will be instrumental as we advance bexotegrast toward approval.”
"I am delighted to be joining Pliant at this important time in the Company's evolution," said Dr. Imbert. "As Pliant advances its portfolio, I look forward to contributing my expertise in CMC technical operations and commercial-stage readiness to assist in delivering potentially important treatments to patients in need.”
Dr. Imbert is a seasoned biopharmaceutical leader who brings 25 years of technical manufacturing operations experience to Pliant. Most recently, Dr. Imbert served as Senior Vice President of CMC and Technical Operations at Chinook Therapeutics (acquired by Novartis). As a member of the Executive Committee, Dr. Imbert built and managed a fully outsourced CMC, manufacturing and supply chain organization in support of Chinook’s global Phase 1 to Phase 3 clinical trials and successfully led change management initiatives in support of assets transition into Novartis. Prior to Chinook, Dr. Imbert held the role of Senior Vice President of Pharmaceutical Sciences at Dermira (acquired by Eli Lily and Company). Over her 10-year tenure, she established fully virtual CMC, manufacturing and supply chain capabilities in a fit-for-purpose manner in support of a broad portfolio of small molecules and biologics to Phase 3 as well as the launch of QBREXZA®. Prior to Dermira, Dr. Imbert held research and development leadership roles of increasing seniority at Anacor Pharmaceuticals (acquired by Pfizer), most recently serving as Vice President of Pharmaceutical Research and Development. Earlier in her career, Dr. Imbert held scientific and product development roles at Alza Corporation (a Johnson & Johnson company) and Cellegy Pharmaceuticals. Dr. Imbert graduated with an engineering degree from Ecole Nationale Supérieure de Chimie de Paris (Chimie ParisTech) and received a Ph.D. in Pharmaceutical Sciences from the University of Cincinnati. Dr. Imbert was also a NIH Postdoctoral Scholar at the University of California San Francisco.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or IPF. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency in IPF. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn, and Facebook.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding the Company’s current and future commercial plans and strategies, including the Company’s goal of becoming the leader in the treatment of pulmonary fibrosis and rare fibrotic pulmonary diseases and developing important treatments for patients in need. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of current macroeconomic and marketplace conditions on our business, operations, clinical supply and plans, our reliance on third parties for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, including the availability of additional term loans under our loan facility, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the period ended September 30, 2024, which is available on the SEC's website at www.sec.gov. Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
QBREXZA® is a registered trademark of Journey Medical Corporation.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6fa80549-07ec-4eed-adb9-1587172567b6
FAQ
What is Dr. Delphine Imbert's role at Pliant Therapeutics (PLRX)?
What experience does Dr. Imbert bring to PLRX?
How will Dr. Imbert's appointment impact PLRX's bexotegrast development?
What was Dr. Imbert's most recent position before joining PLRX?
